2023
43250 Efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups: Analysis From ESTEEM 1 and ESTEEM 2
Langley R, Mehta N, Crowley J, Deignan C, Cheng S, Chen M, Wang W, Strober B. 43250 Efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups: Analysis From ESTEEM 1 and ESTEEM 2. Journal Of The American Academy Of Dermatology 2023, 89: ab158. DOI: 10.1016/j.jaad.2023.07.635.Peer-Reviewed Original Research
2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal Of Dermatological Science 2019, 96: 126-133. PMID: 31787506, DOI: 10.1016/j.jdermsci.2019.09.003.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisIL-17APlaque psoriasisIL-22Week 16T cellsRegulatory T cell numbersT helper 17 (Th17) cellsEfficacy of apremilastIL-23 levelsTotal T cellsPlasma cytokine levelsRegulatory T cellsT cell numbersMedian percentage reductionPathogenesis of psoriasisSevere psoriasisCardiometabolic biomarkersClinical improvementCytokine levelsInflammatory biomarkersIL-17FWeeks 0Clinical trialsWeek 4
2017
Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
Bagel J, Lebwohl M, Stein Gold L, Jackson J, Goncalves J, Levi E, Callis Duffin K, Strober B. Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study). SKIN The Journal Of Cutaneous Medicine 2017, 1: s13. DOI: 10.25251/skin.1.supp.12.Peer-Reviewed Original ResearchEfficacy of apremilastModerate plaque psoriasisPlaque psoriasisLife measuresPsoriasisPatientsApremilastCelgene